SEC Form 4 · accession 0001209191-18-005831
Yarrow Bioscience, Inc. · YARW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Remeditex Ventures LLC
10% Owner
Period of report
Jan 25, 2018
Accepted (ET)
Jan 29, 2018 · 4:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001566044
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 25, 2018 | P | 100,000 | $17.00 | A | 1,582,854 | D | |
| Common StockF1 | Jan 29, 2018 | C | 2,650 | — | A | 1,585,504 | D | |
| Common StockF1 | Jan 29, 2018 | C | 871,583 | — | A | 2,457,087 | D | |
| Common StockF1 | Jan 29, 2018 | C | 304,576 | — | A | 2,761,663 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF1 | — | Jan 29, 2018 | C | 7,150 | D | — | — | Common Stock | 2,650 | 0 | D |
| Series B Preferred StockF1 | — | Jan 29, 2018 | C | 2,351,097 | D | — | — | Common Stock | 871,583 | 0 | D |
| Series C Preferred StockF1 | — | Jan 29, 2018 | C | 821,596 | D | — | — | Common Stock | 304,576 | 0 | D |
Explanation of responses
- F1Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.